Company Description
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products.
The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 1983 |
| IPO Date | Apr 29, 1993 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 235 |
| CEO | Stephen Griffin |
Contact Details
Address: 32 Wiggins Avenue Bedford, Massachusetts 01730 United States | |
| Phone | 781 457 9000 |
| Website | anika.com |
Stock Details
| Ticker Symbol | ANIK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000898437 |
| CUSIP Number | 035255108 |
| ISIN Number | US0352551081 |
| Employer ID | 04-3145961 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Stephen D. Griffin | President, Principal Financial Officer, Chief Executive Officer and Director |
| Dr. Cheryl Renee Blanchard Ph.D. | Executive Chair |
| Matthew Hall | Director of Corporate Development and Investor Relations |
| James Chase | Senior Vice President of International Sales and Marketing |
| Ben Joseph | Vice President of Commercial and Corporate Development |
| Lisa Funiciello | Vice President and Chief Human Resources Officer |
| Mira Leiwant | Senior Vice President of Regulatory, Quality and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | SCHEDULE 13G | Filing |
| Apr 29, 2026 | 8-K | Current Report |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 3, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Jan 27, 2026 | SCHEDULE 13D/A | Filing |